{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:06:48Z","timestamp":1791104808842,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1136\/ard.2008.105692","type":"journal-article","created":{"date-parts":[[2009,3,17]],"date-time":"2009-03-17T00:13:17Z","timestamp":1237248797000},"page":"434-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events"],"prefix":"10.1016","volume":"69","author":[{"given":"E","family":"Lozano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Corbera-Bellalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Garc\u00eda-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Esp\u00edgol-Frigol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pl\u00e0-Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.105692_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis.","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/ard.2008.105692_bib2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","article-title":"Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis.","volume":"121","author":"Weyand","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2008.105692_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","article-title":"Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.","volume":"43","author":"Hernandez-Rodriguez","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.105692_bib4","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","article-title":"Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.","volume":"107","author":"Hernandez-Rodriguez","year":"2003","journal-title":"Circulation"},{"key":"10.1136\/ard.2008.105692_bib5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/rheumatology\/kel128","article-title":"Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis.","volume":"45","author":"Cid","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.105692_bib6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.RES.84.9.1050","article-title":"Tissue destructive macrophages in giant cell arteritis.","volume":"84","author":"Rittner","year":"1999","journal-title":"Circ Res"},{"key":"10.1136\/ard.2008.105692_bib7","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1136\/ard.2006.068148","article-title":"Gelatinase expression and activity in giant-cell arteritis lesions.","volume":"66","author":"Segarra","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.105692_bib8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/1529-0131(199804)41:4<623::AID-ART9>3.0.CO;2-6","article-title":"Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis.","volume":"41","author":"Kaiser","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105692_bib9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/ard.2007.070805","article-title":"Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant-cell arteritis.","volume":"67","author":"Lozano","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.105692_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","article-title":"Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis.","volume":"41","author":"Cid","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105692_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1034\/j.1600-0420.2002.800403.x","article-title":"Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature.","volume":"80","author":"Hayreh","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1136\/ard.2008.105692_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.21075","article-title":"Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis.","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105692_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","article-title":"Risk factors for cranial ischemic complications in giant cell arteritis.","volume":"83","author":"Nesher","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard.2008.105692_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","article-title":"Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients.","volume":"79","author":"Gonzalez-Gay","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard.2008.105692_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/rheumatology\/36.2.251","article-title":"Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis.","volume":"36","author":"Font","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2008.105692_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/art.11464","article-title":"Domains of health-related quality of life important to patients with giant cell arteritis.","volume":"49","author":"Hellmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105692_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/brain\/82.3.377","article-title":"The visual changes in temporal (giant-cell) arteritis. Report of a case with autopsy findings.","volume":"82","author":"Crompton","year":"1959","journal-title":"Brain"},{"key":"10.1136\/ard.2008.105692_bib18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/bjo.47.9.555","article-title":"Temporal arteritis.","volume":"47","author":"Whitfield","year":"1963","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2008.105692_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.53.1.177","article-title":"Pathologic findings in a steroid-responsive optic nerve infarct in giant-cell arteritis.","volume":"53","author":"Kattah","year":"1999","journal-title":"Neurology"},{"key":"10.1136\/ard.2008.105692_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM199508103330607","article-title":"Endothelins.","volume":"333","author":"Levin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.105692_bib21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","article-title":"Endothelin system: the double-edged sword in health and disease.","volume":"41","author":"Kedzierski","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1136\/ard.2008.105692_bib22","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1161\/CIRCULATIONAHA.105.609271","article-title":"Endothelin: beyond a vasoconstrictor.","volume":"113","author":"Gossl","year":"2006","journal-title":"Circulation"},{"key":"10.1136\/ard.2008.105692_bib23","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/01.CIR.102.19.2434","article-title":"Endothelins and endothelin receptor antagonists therapeutic considerations for a novel class of cardiovascular drugs.","volume":"102","author":"Luscher","year":"2000","journal-title":"Circulation"},{"key":"10.1136\/ard.2008.105692_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells.","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1136\/ard.2008.105692_bib25","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.172.6.1741","article-title":"Endothelins, peptides with potent vasoactive properties, are produced by human macrophages.","volume":"172","author":"Ehrenreich","year":"1990","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2008.105692_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art1.10161","article-title":"A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.","volume":"47","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105692_bib27","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000030185.67510.C0","article-title":"Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis.","volume":"106","author":"Cid","year":"2002","journal-title":"Circulation"},{"key":"10.1136\/ard.2008.105692_bib28","doi-asserted-by":"crossref","unstructured":"Kleinman HK, Cid MC,. Preparation of endothelial cells. In: Bonifacino JS, Dasso M, Harford JB, et al, eds. Current protocols in cell biology. New York: John Wiley and Sons, Inc, 1998:unit 2.3 pp1\u20134.","DOI":"10.1002\/0471143030.cb0203s00"},{"key":"10.1136\/ard.2008.105692_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vph.2005.03.004","article-title":"Vascular endothelin in hypertension.","volume":"43","author":"Schiffrin","year":"2005","journal-title":"Vascul Pharmacol"},{"key":"10.1136\/ard.2008.105692_bib30","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/art.10895","article-title":"Endothelin and endothelin receptor antagonists in systemic rheumatic disease.","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105692_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0002-9394(01)01202-8","article-title":"Increased endothelin-1 plasma levels in giant cell arteritis: a report on four patients.","volume":"133","author":"Pache","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1136\/ard.2008.105692_bib32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1172\/JCI115367","article-title":"Hypoxia induces endothelin gene expression and secretion in cultured human endothelium.","volume":"88","author":"Kourembanas","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2008.105692_bib33","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1161\/01.CIR.89.4.1580","article-title":"Endothelin in human congestive heart failure.","volume":"89","author":"Wei","year":"1994","journal-title":"Circulation"},{"key":"10.1136\/ard.2008.105692_bib34","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1161\/CIRCULATIONAHA.104.503540","article-title":"Pulmonary arterial hypertension.","volume":"114","author":"McLaughlin","year":"2006","journal-title":"Circulation"},{"key":"10.1136\/ard.2008.105692_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.95.2.357","article-title":"Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo.","volume":"95","author":"Hasdai","year":"1997","journal-title":"Circulation"},{"key":"10.1136\/ard.2008.105692_bib36","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/01.ATV.0000209501.56852.6c","article-title":"Dynamics and plasticity of Weibel\u2013Palade bodies in endothelial cells.","volume":"26","author":"Rondaij","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1136\/ard.2008.105692_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(00)00642-7","article-title":"Cytokine enhancement of endothelin ET(B) receptor-mediated contraction in human temporal artery.","volume":"406","author":"White","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1136\/ard.2008.105692_bib38","doi-asserted-by":"crossref","unstructured":"Cid MC, Garcia-Martinez A, Lozano E, et al. Five clinical conundrums in the management of giant cell arteritis. Rheum Dis Clin North Am 2007;33:819\u201334, vii.","DOI":"10.1016\/j.rdc.2007.08.001"},{"key":"10.1136\/ard.2008.105692_bib39","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0161-6420(03)00228-8","article-title":"Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy.","volume":"110","author":"Hayreh","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2008.105692_bib40","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","article-title":"Poor prognosis of visual outcome after visual loss from giant cell arteritis.","volume":"112","author":"Danesh-Meyer","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2008.105692_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.105692_bib42","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724196355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724196355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.105692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T14:13:33Z","timestamp":1736086413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724196355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0003496724196355"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.105692","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.105692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc. Publishing Group Ltd and European League Against Rheumatism. All rights reserved. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}